Electromed Posts 16.3% Revenue Growth to $18.9M and 42% Operating Income Rise
Electromed reported record FQ2 2026 net revenues of $18.9 million, up 16.3% year-over-year, with core home care sales rising 18.4% to $17.3 million. Operating income jumped 42.4% to $3.6 million and net income reached $2.8 million, resulting in earnings per share of $0.32.
1. Q2 2026 Financial Performance
Electromed achieved its 13th consecutive quarter of year-over-year revenue and profit growth, delivering record net revenues of $18.9 million. Core home care revenue grew 18.4% to $17.3 million, supported by a sales force averaging $1.2 million in annualized revenue per representative.
2. FDA Approval and SmartVest Integration
The February launch of Brensupri, the first FDA-approved drug for bronchiectasis, has boosted awareness of Electromed’s airway clearance therapy. This approval complements the company’s SmartVest system, enhancing its position in pulmonary care treatment.
3. Payer Contracts and Market Expansion
Management executed 25 new payer contracts, adding coverage for 2.9 million lives and targeting 58% of qualifying patients not yet receiving HFCWO therapy. This expansion aims to close the treatment gap in home care pulmonary therapy.